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Aim To determine the differences in plasma homocysteine 
levels between three MTHFR 677 genotype subgroups in 
patients with thrombosis and in controls, as well as be-
tween patients with thrombosis and controls with the 
same MTHFR 677 genotype.
Methods This case-control study was conducted in Clin-
ical Center of Vojvodina, Novi Sad, from June to Decem-
ber 2011. We included 65 patients with either arterial or 
venous thrombosis (mean age, 40.97 ± 11.38 years) and 65 
controls with no history or clinical evidence of any throm-
botic event (mean age, 41.23 ± 11.12 years). Patients and 
controls were age- and sex-matched.
Results In comparison with controls, thrombotic patients 
had significantly higher homocysteine levels (12.81 ± 4.94 
µmol/L vs 9.82 ± 3.68 µmol/L; P < 0.001) and significant-
ly higher incidence of hyperhomocysteinemia (55% vs 
22%; P < 0.001; odds ratio [OR] = 4.521). There were no sig-
nificant differences in homocysteine levels between ho-
mozygous carriers, heterozygous carriers, and non-carriers 
of the MTHFR 677 mutation in either thrombotic patients 
(12.97 ± 5.40 µmol/L vs 12.55 ± 5.71 µmol/L vs 13.27 ± 1.71 
µmol/L; P = 0.100) or controls (10.07 ± 2.50 µmol/L vs 
10.25 ± 4.84 µmol/L vs 9.20 ± 2.44 µmol/L; P = 0.651). How-
ever, in comparison with controls, homozygous carriers in 
thrombotic patient group did not have significantly higher 
levels of homocysteine (12.97 ± 5.40 µmol/L vs 10.07 ± 2.50 
µmol/L; P = 0.072), but heterozygous carriers (12.55 ± 5.71 
µmol/L vs 10.25 ± 4.84 µmol/L; P = 0.020) and non-carriers 
(13.27 ± 1.71 µmol/L vs 9.20 ± 2.44 µmol/L; P < 0.001) did. 
There was no significant difference in homocysteine lev-
els between patients with arterial and venous thrombosis 
(12.76 ± 3.60 µmol/L vs 12.86 ± 5.51 µmol/L; P = 0.990) and 
between patients with one thrombotic event and those 
with recurrent thrombotic events (12.14 ± 3.20 µmol/L vs 
15.25 ± 8.51 µmol/L; P = 0.254).
Conclusion Plasma homocysteine levels have a greater 
clinical significance in the prevention of thrombosis and 
managing its complications than MTHFR 677 genotyping.
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Nowadays, thrombosis is a leading cause of morbidity and 
mortality in most countries (1). The ensuing complications, 
the most serious of which is myocardial infarction, stroke, 
and pulmonary thromboembolism may cause long-term 
and severe disability. They increasingly affect younger pop-
ulations and generate a great social and economic burden. 
There are hence continuing efforts to discover biochemi-
cal markers that would enable more reliable risk stratifica-
tion (2). Considering that it is not uncommon that none of 
the five major risk factors for thrombosis is recognized in a 
patient presenting with complications of thrombosis, the 
last few years have witnessed intensified research on new 
risk factors and unveiling their effects on the pathogenesis 
of the thrombotic process (3). According to the data for the 
last ten years reported by the American Heart Association, 
the most convincing results have been obtained in studies 
on C-reactive protein (CRP), Lp(a) lipoprotein, apolipopro-
tein apo(a), fibrinogen, and homocysteine (4).
Homocysteine is an aminothiol compound, which is the 
main metabolite of an essential amino acid, methionine. 
Homocysteine metabolism involves either remethylation 
to methionine or its irreversible metabolism to produce 
cysteine (5). The so-called homocysteine hypothesis of 
atherosclerosis, according to which even moderately el-
evated homocysteine levels may cause progression of 
atherosclerosis, was first postulated by McCully in 1969 
(6), whereas the first evidence on the relation between 
pathological homocysteine metabolism and coronary 
disease in general population was provided by Wilcken 
and Wilcken in 1976 (7). The interest in homocysteine 
as a risk factor for development of thrombosis has been 
dramatically increasing since 1990, and it is still in the fo-
cus of attention of the scientific community. Hyperho-
mocysteinemia may result from a number of dietary and 
lifestyle factors, genetic factors, nutritional deficiencies, 
and other etiological factors (8-11). The most common 
form of genetically determined hyperhomocysteinemia 
is caused by the occurrence of a thermo-liable variant of 
methylenetetrahydrofolate reductase (tMTHFR), an en-
zyme involved in homocysteine metabolism, whose en-
zymatic activity is significantly reduced in hyperhomo-
cysteinemia. The most frequent mutation leading to the 
manifestation of thermo liability of this enzyme is muta-
tion of the MTHFR 677 gene, caused by alanine to valine 
substitution (12). The incidence of this mutation is rela-
tively high, although it varies in different ethnic groups 
(13). It has still not been elucidated whether the degree 
of hyperhomocysteinemia is significantly higher in ho-
mozygous than in heterozygous carriers, however, it has 
been shown that hyperhomocysteinemia in the presence 
of this genetic mutation manifests only in the case of low 
folate levels, making folate deficiency a likely explana-
tion for the expression of the MTHFR thermo liable geno-
type (14-16). The importance of clear understanding of 
the role of hyperhomocysteinemia in the etiopathogen-
esis of thrombosis is underlined by the fact that it can be 
corrected easily by simple dietary supplementation with 
group B vitamins and folic acid. If hyperhomocysteinemia 
is definitely confirmed to be an independent risk factor 
for thrombosis, this could be an efficient, safe, simple, and 
cost-effective means of preventing one of the major risk 
factors for this disease.
Efficient recognition and management of risk factors for 
thrombosis are very important, and cost-effective meth-
ods for detecting risk factors are necessary for routine clini-
cal treatment and prevention of this disease. The aim of our 
study was to determine the differences in plasma homo-
cysteine levels between three MTHFR 677 genotype sub-
groups in patients with thrombosis and controls, as well as 
between patients with thrombosis and controls with same 
MTHFR 677 genotype.
MATeRIAL And MeThodS
Study design and participants
This case-control study was conducted at the Center for 
Laboratory Medicine of the Clinical Center of Vojvodina 
in Novi Sad, Serbia and included 130 participants of both 
sexes, aged 17 to 59 years. There were 65 thrombotic pa-
tients; 36 male and 29 female, aged 17 to 59 years (mean 
age ± standard deviation 40.97 ± 11.38 years). Among 
these, 19 had arterial and 46 venous thrombosis. In order 
to avoid potential influence of acute illness on the studied 
parameters only patients who had suffered a thrombotic 
event at least six weeks prior to enrollment were selected. 
The exclusion criteria were previously verified disorders of 
the hemostatic mechanism, renal insufficiency, gastroin-
testinal disorders, autoimmune disease, diabetes, thyroid 
disorders, malignancy, and consumption of alcohol or sub-
stances affecting homocysteine metabolism. At the time 
of blood sampling, none of the participants had an acute 
illness that could affect the study results. Blood samples 
were collected after overnight fasting, with the last meal 
being a light one. Blood sampling was done with partici-
pants sitting. Collected blood was put in a container with 
ice and centrifuged for half an hour, and analyses were 
performed immediately thereafter.
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The control group consisted of 65 healthy Clinical Cen-
ter of Vojvodina employees who were personally asked to 
participate in the study during regular working time; 31 
women and 34 men aged 18 to 58 years (mean age ± stan-
dard deviation 41.23 ± 11.12 years). Except for the pres-
ence of thrombosis, the inclusion and exclusion criteria for 
the control group were identical to those applied for the 
cases. Control participants underwent the same laborato-
ry analyses as cases. Prior to the study, informed consent 
was taken from all the participants. The study protocol was 
approved by the institutional ethics committee of Clinical 
Center of Vojvodina.
Laboratory methods
Plasma homocysteine levels were determined using the 
fluorescence polarization immunoassay method (17). Hy-
perhomocysteinemia was defined as plasma homocysteine 
levels above 12 µmol/L. This cut-off value was selected since 
the previous upper reference limit of 15 µmol/L has been 
suggested to be inappropriately high (18). For most Euro-
pean populations, the recommended homocysteine level is 
less than 10 µmol/L. Homocysteine levels between 10 and 
12 µmol/L are considered tolerable, while those ranging 
from 12 to 15 µmol/L represent a borderline for hyperho-
mocysteinemia (19). Results of the Framingham study (18) 
revealed an increase in cardiovascular risk in individuals with 
homocysteine levels of 11.4 µmol/L, and some authors (19) 
reported a double increase in the risk of vascular damage as-
sociated with homocysteine levels higher than 10.2 µmol/L. 
Furthermore, it is recommended to determine reference val-
ues for every population since there are a variety of factors 
affecting them (20). Based on the results of healthy Serbian 
population, the Center of Laboratory Medicine of Clinical 
Center of Vojvodina adopted 5-12 µmol/L as the reference 
value. Serum folic acid level was measured using an ion-
capture method (21). The assays were performed on an AX-
SYM instrument with commercially available ABBOTT GmbH 
&Co.KG (Abbot Diagnostics, Wiesbaden, Germany) immuno-
assay kits. A polymerase chain reaction (PCR)-based method 
was employed for MTHFR 677 genotyping. Capillary blood 
samples were collected from participants and processed 
shortly afterwards. Genomic DNA was isolated and puri-
fied from dried blood spots using the Chelex100®Molecular 
Grade Resin reagent (Bio-Rad, Hercules, CA, USA) following 
the manufacturer’s instructions. Detection of the MTHFR 
677 C or MTHFR 677 T allele in the patients was performed 
by real-time PCR on ABI PRISM 7000 Sequence Detection 
System instrument (Applied Biosystems, Foster City, CA, 
USA) using the assay for allelic discrimination. For the 
amplification reactions, a set of primers and specific probes 
for the differentiation between wild allele and MTHFR 677 T 
alelle, designed and synthesized by the TaqMan SNP Geno-
typing service (Applied Biosystems, Foster City, CA, USA) was 
used. Diluted samples and the Taqman Universal PCR Master 
Mix (Applied Biosystems) set of reagents were added (22). 
The initial denaturation was carried out for 10- minutes at 
95°C. The conditions for 40 cycles of amplification were de-
naturation at 95°C for 15 seconds and annealing and exten-
sion at 60°C for 60 seconds.
Statistical analysis
Statistical analyses were performed using the Statistica 10 
(StatSoft Inc., Tulsa, OK, USA) software. Normality of the 
distribution was determined using Kolmogorov-Smirnov 
test. Mean values and standard deviations were calculat-
ed for each investigated numerical variable. Comparison 
of distributions of homocysteine levels for different groups 
was tested by Mann-Whitney test and Kruskal-Wallis test. 
Kruskal-Wallis test was followed by multiple comparison of 
mean rank test if necessary. Comparison of proportions of 
observed categorical variables was tested using Pearson 
χ2 test. From the contingency tables, odds ratios (OR) for 
proportions of observed characteristics and correspond-
ing confidence intervals (CI) were calculated and tested for 
significance. As a measure of correlation, Spearman’s rank 
correlation coefficient was calculated. The level of signifi-
cance was set at 0.05.
ReSuLTS
Age and homocysteine level were tested for normality of 
the distributions using Kolmogorov-Smirnov test. The dis-
tribution of both variables differed significantly from nor-
mal (age D = 0.121, P < 0.05; homocysteine level, D = 0.147, 
P < 0.01). Case and control groups did not differ in age 
(40.97 ± 11.38 years vs 41.23 ± 11.12 years; P = 0.854) and 
sex (cases: 36 male and 29 female; controls: 34 male and 31 
female; P = 0.725). We divided the case and control group 
into three subgroups each, according to age intervals, in 
order to exclude the possible influence of age on homo-
cysteine level. The first subgroup consisted of participants 
younger than 31 years, the second of participants aged 31 
to 45 years, and the third of participants aged 46 to 59 years. 
There was no significant difference in sex and age among 
these subgroups of patients and controls (Table 1).
Cases had significantly higher mean homocysteine level than 
controls (12.3 ± 4.94 µmol/L vs 9.2 ± 3.68 µmol/L; P < 0.001) 
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and a significantly higher proportion of hyperhomocysteine-
mia (55% vs 22%; P < 0.001; OR 4.522, 95% CI 2.099-9.741). 
Homocysteine levels were significantly higher in both men 
with thrombosis than in control men (12.65 ± 5.72 µmol/L 
vs 9.65 ± 2.35 µmol/L; P < 0.001) and women with thrombo-
sis than control women (11.25 ± 3.29 µmol/L vs 8.95 ± 4.77 
µmol/L; P = 0.024), but there was no difference in the pro-
portion of participants with hyperhomocysteinemia be-
tween women with thrombosis and control women (41% vs 
23%; P = 0.118; OR 2.420, 95% CI 0.789-7.419, P = 0.061), while 
men with thrombosis had significantly higher proportion 
of hyperhomocysteinemia than control men (55% vs 22%; 
P < 0.001; OR 4.52, 95% CI 2.099-9.741) (Table 2). There was 
no significant difference in homocysteine levels between 
men and women in the control group (9.65 ± 2.35 µmol/L vs 
8.95 ± 4.77 µmol/L; P = 0.396), whereas men with thrombosis 
had significantly higher homocysteine levels than women 
with thrombosis (12.65 ± 5.72 µmol/L vs 11.25 ± 3.29 µmol/L; 
P = 0.018). Similarly, control men and women did not signif-
icantly differ in the proportion of participants with hyper-
homocysteinemia (21% vs 23%; P = 0.845; OR 1.125; 95%CI 
0.345-3.673, P = 0.4226), whereas in the case group it was 
significantly higher in men (67% vs 41%; P = 0.041; OR 2.834, 
95%CI 1.029-7.803, P = 0.022) (Table 2).
TABLe 1. Characteristics of patients with thrombosis and the control group
no. (%) of
patients (n = 65) controls (n = 65) P
Age (years, mean ± standard deviation) 40.97 ± 11.38 41.23 ± 11.12 0.894*
Age groups
<31 (n, mean ± standard deviation) (14) 24.14 ± 3.90 (11) 25.09 ± 4.32 0.571*
male 12 (86)  9 (82) 0.792†
female  2 (14)  2 (18)
31-45 (n, mean ± standard deviation) (23) 38.35 ± 4.36 (27) 36.18 ± 3.37 0.054*
male 10 (43) 11 (41) 0.846†
female 13 (57) 16 (59)
46-59 (n, mean ± standard deviation) (28) 51.54 ± 3.97 (27) 52.85 ± 3.01 0.173
male 14 (50) 14 (52) 0.890†
female 14 (50) 13 (48)
Sex
male 36 (55.4) 34 (52.3) 0.725†
female 29 (44.6) 31 (47.7)
*Mann-Whitney test.
†χ2-test.
TABLe 2. Comparison of homocysteine levels in male and female participants in case and control groups and the proportion of 
participants with hyperhomocysteinemia
Characteristics Case group Control group
P (odds ratio[oR]and 
95%confidence interval [CI])
Homocysteine, median (range), µmol/L 12.3 (10.5-14.2)  9.2 (7.7-11.3) <0.001*
Male 12.65 (11.51-14.85)  9.65 (8.12-11.28) <0.001*
Female 11.25 (9.01-12.74)  8.95 (7.48-11.12)  0.024*
P  0.018*  0.397*
<31 12.41 (11.33-13.19)  9.80 (8.85-12.04)
31-45 11.87 (10.46-12.73)  9.20 (6.71-10.76)
46-59 12.62 (10.4-15.0)  8.92 (7.91-11.8)
P  0.497†  0.442†
Proportion of participants with hyperhomocysteinemia, (%) 36 (55) 14 (22) <0.001‡ (4.52, 2.099-9.741)
Male 24 (67)  7 (20) <0.001‡ (7.72, 2.614-22.767)
Female 12 (41)  7 (23)  0.118 ‡ (2.42, 0.789-7.419)
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There was no significant difference in homocysteine lev-
els between participants with arterial thrombosis and 
those with venous thrombosis (12.76 ± 3.60 µmol/L vs 
12.87 ± 5.51 µmol/L; P = 0.988), and between cases with 
one thrombotic event and those with recurrent throm-
botic events (12.14 ± 3.20 µmol/L vs 15.26 ± 8.51 µmol/L; 
P = 0.254) (Table 3).
On the basis of the results of genetic testing for mutations 
in the MTHFR 677 gene, cases and controls were catego-
rized into homozygous carriers of the mutation (677 T/T), 
heterozygous carriers (677 T/C), and non-carriers of the 
mutation (677 C/C). There were no significant differences 
in homocysteine levels between the three case subgroups 
(12.97 ± 5.39 vs 12.55 ± 5.71 vs 13.27 ± 1.72; P = 0.100), as 
well as between the three control subgroups (10.07 ± 2.50 
vs 10.25 ± 4.84 vs 9.21 ± 2.44; P = 0.651) (Figure 1). There was 
also no significant difference in homocysteine levels be-
tween 677 T/T carriers in the case group and 677 T/T car-
riers in control group (12.97 ± 5.39 µmol/L vs 10.07 ± 2.50 
µmol/L; P = 0.072), but there was a significant difference be-
tween 677 T/C carriers in the case group and 677 T/C carri-
ers in the control group (12.55 ± 5.71 µmol/L vs 10.25 ± 4.84 
µmol/L; P = 0.020), and between non-carriers in the case 
and non-carriers in the control group (13.27 ± 1.72 µmol/L 
vs 9.21 ± 2.44 µmol/L; P < 0.001) (Figure 1) implying that 
MTHFR 677 genotype does not have a crucial effect on 
plasma homocysteine levels.
In order to investigate whether sex and age influence the 
results, we analyzed their potential effects. We found no 
significant association between sex and MTHFR 677 geno-
type in all participants together (P = 0.131), in cases only 
(P = 0.786), and in controls only (P = 0.081). Similarly, there 
was no significant association between age and MTHFR 
677 genotype in all participants together (P = 0.467), cases 
only (P = 0.451), and controls only (P = 0.564) (Table 4). Sig-
nificant Spearman’s rank correlation coefficients between 
levels of folic acid and homocysteine were found both 
in cases and controls (r = -0.353; P = 0.004 and r = -0.562; 
P ≤ 0.001, respectively) (Figure 2).
In order to elucidate these findings, we first assessed the 
correlation of homocysteine and folic acid levels and 
found a negative correlation between these two param-
eters. After that, we analyzed the levels of folic acid among 
the subgroups and found that non-carriers of MTHFR 677 
mutation on average had significantly lower folate levels 
than heterozygous and homozygous carriers. Analysis of 





 level in µmol/L 
(mean±Sd*) P
Type of thrombosis:
arterial 18 12.76 ± 3.60 0.988†
venous 47 12.87 ± 5.51
number of thrombotic events:
one 51 12.14 ± 3.20 0.254†
more than one 14 15.26 ± 8.51
*Sd – standard deviation.
†Mann-Whitney test.
FIGuRe 1. Box Plot of homocysteine levels in different subgroups categorized accord-
ing to MThFR genotype
FIGuRe 2. Correlation between homocysteine and folic acid levels in case and control 
group
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individual patients showed that the patients with the low-
est levels of folic acid in the group of non-carriers of MTH-
FR 677 mutation had the most pronounced hyperhomo-
cysteinemia.
dISCuSSIon
Consistent with our expectations, this study found that ho-
mocysteine levels and the proportion of participants with 
hyperhomocysteinemia were significantly higher in indi-
viduals with thrombosis than in healthy participants. Al-
though a great number of studies shows that elevated ho-
mocysteine levels clearly contribute to the development of 
thrombosis and the ensuing complications (23-25), there 
are data suggesting that elevated homocysteine levels are 
merely a consequence and not the cause of vascular dis-
ease (26). The proposed pathophysiological mechanisms 
by which hyperhomocysteinemia disrupts vascular physi-
ology and contributes to the development of thrombosis 
include endothelial dysfunction as result of oxidation and 
tyrosine nitration of small and intermediate conductance 
Ca2+-activated potassium channels resulting in impaired 
endothelium-derived hyperpolarizing factor-mediated 
relaxation of resistance arterioles (27-29), oxidative modi-
fication of low density lipoproteins (LDL) particles (30), in-
crease in lipid uptake and retention by blood vessel walls, 
increased adhesion of monocytes to the blood vessel wall, 
stimulation of smooth muscle proliferation (31), activation 
of inflammatory pathways (32), thrombocytic dysfunction 
(33), and activation of procoagulant factors of the hemo-
static mechanism (27).
According to our results, patients with arterial and ve-
nous thrombosis did not have significantly different ho-
mocysteine levels, but considering that those subgroups 
were small and that arterial thrombosis and venous throm-
bosis patients comparison was not the aim of our study, 
we are planning on performing a more detailed analysis of 
these parameters including more participants, alongside 
with comparison of genotypes in these subgroups. There 
was no significant difference in homocysteine levels be-
tween patients who had one thrombotic event and those 
with recurrent thrombotic events, however, definite con-
clusions about this issue require a long-term prospective 
patient follow-up.
We found no significant differences in homocysteine 
levels and the proportion of patients with hyperhomo-
cysteinemia between the subgroups of homozygous car-
riers, heterozygous carriers, and non-carriers of MTHFR 677 
among cases. The same results were obtained for control 
participants. There was also no significant difference be-
tween homozygous carriers in thrombotic patients group 
and homozygous carriers in the control group. However, a 
significant difference between heterozygous carriers and 
non-carriers in thrombotic patients group compared to 
controls was found. These results suggest that the MTH-
FR 677 genotype does not have a crucial effect on plasma 
homocysteine levels and that environmental factors may 
have a greater clinical significance. Other recent studies 
have shown similar results and according to their findings 
elevated levels of homocysteine are always significantly 
higher in the group of patients with documented cardio-
vascular events, regardless of the genotype. Also, a weak 
association between the MTHFR C677T polymorphism 
and cardiovascular disease was established, which 
suggests that elevated homocysteine levels, rather 
TABLe 4. Frequency of MThFR genotypes in different sub-
groups categorized according to age and sex










male 22 (32) 29 (41) 19 (27)  70 0.131
female 13 (22) 35 (58) 12 (20)  60
total 35 64 31 130
Cases:
male  9 (25) 18 (50)  9 (25)  36 0.786
female  6 (21) 17 (59)  6 (20)  29 
total 15 35 15  65
Controls:
male 13 (39) 11 (31) 10 (30) 34 0.081
female  7 (23) 18 (58)  6 (19)  31
total 20 29 16  65
Cases and controls:
<31 y  9 (36)  8 (32)  8 (32)  25 0.467
31-45 y 13 (26) 26 (52) 11 (22)  50
46-59 y 13 (24) 30 (54) 12 (22)  55
total 35 64 31 130
Cases:
<31 y  4 (28)  5 (36)  5 (36)  14 0.451
31-45 y  4 (17) 13 (57)  6 (26)  23
46-59 y  7 (25) 17 (61)  4 (14)  28
total 15 35 15  65
Controls:
<31 y  5 (46)  3 (27)  3 (27)  11 0.564
31-45 y  9 (33) 13 (48)  5 (19)  27
46-59 y  6 (23) 13 (46)  8 (31)  27
total 20 29 16  65
*χ2-test.
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than the 677 genotype, are associated with development 
of thrombosis (34,35). Whereas some studies show a clear 
association between the MTHFR 677 mutation and an in-
creased risk of ischemic heart and brain disease (36), oth-
ers conclude that the association between the MTHFR 
677 mutation and an increased cardiovascular risk mani-
fests only in individuals with low folate levels (37). There-
fore, it is important to point out that previous research 
clearly shows that folate status plays an important role 
in suppressing negative expression of tMTHFR and in ho-
mocysteine concentration (38,39). The influence of folate 
on homocysteine concentrations is thus one of the best 
examples of nutritional ecogenetics (7). Furthermore, the 
finding that homozygosity for the MTHFR 677 mutation re-
quires increased folate intake in order to keep normal ho-
mocysteine values corroborates the fact that individual vi-
tamin needs depend on the genetic base (13). However, 
many other vitamins also have important roles in homo-
cysteine metabolism. Some recent studies show that vita-
min B12 may have a key role in vitamin therapy used to low-
er homocysteine levels in stroke prevention interventions. 
Furthermore, there are data confirming that high con-
sumption of Ω-3 polyunsaturated fatty acids lowers plas-
ma homocysteine (40). Therefore, the best way to evaluate 
real influence of environmental factors on homocysteine 
levels is to determine not only the level of folic acid, but 
also effects of other vitamins and factors that have been 
proven to influence homocysteine levels, such as smoking 
or sedentary lifestyle.
Limitations of the study include a small sample, as well 
as different number of patients with arterial and venous 
thrombotic events. On the other hand, the goal was not to 
evaluate the association of the type of thrombosis with ho-
mocystein level, but to estimate the significance of geno-
typing MTHFR mutation. An advantage of the study is that 
we found a cost-effective approach used for identification 
of individuals at increased risk for thromboembolic disease.
Finally, we would like to emphasize that hypehomo-
cysteinemia is now a generally recognized risk factor for 
thrombosis, which is grounded in the results of numerous 
large-scale clinical and epidemiological studies, as well 
as basic scientific research on homocysteine metabolism 
and pathophysiology of elevated homocysteine (36,41-
43). On the other hand, it is still unclear whether hyper-
homocysteinemia is a causal factor in the occurrence of 
thrombosis, a consequence of full-fledged disease, or 
only a biochemical marker of its development. The au-
thors disputing the homocysteine hypothesis postu-
late that the association between hyperhomocysteinemia 
and thrombosis is only an indirect one, via factors affecting 
both homocysteine levels and cardiovascular risk. The lat-
ter assumption is supported by the data indicating that the 
relative risk associated with moderately elevated homo-
cysteine levels has been found to be greater in retrospec-
tive than in prospective studies (44-46). Our results suggest 
that determination of plasma homocysteine concentration 
has a much more significant clinical role in atherothrom-
bosis risk assessment than MTHFR 677 genotyping. How-
ever, definitive conclusions on elevated homocysteine lev-
els as a risk factor for thrombosis can be drawn only after 
publishing of the results of several long-term studies inves-
tigating possibilities of reducing the risk of thrombosis by 
lowering homocysteine levels with vitamin supplementa-
tion therapy (47,48). Until then, the role of homocysteine 
in etiopathogenesis of thrombosis and particularly the 
causes of its elevated plasma levels will remain an issue 
that attracts the attention of scientific community.
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